Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 66

Results For "NIV"

843 News Found

AIkido Pharma improves manufacturing process for pancreatic drug
Biotech | March 04, 2022

AIkido Pharma improves manufacturing process for pancreatic drug

The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug


New CellScape system for high-plex and high-throughput targeted spatial proteomics
Medical Device | March 04, 2022

New CellScape system for high-plex and high-throughput targeted spatial proteomics

ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease


MFine launches heart rate monitoring tool on its App
Startup | March 04, 2022

MFine launches heart rate monitoring tool on its App

It plans launch various other health monitoring tools for smartphones, making existing devices obsolete


Govt announces over Rs 100 crore investment for Ayush sector in Nagaland
Public Health | March 04, 2022

Govt announces over Rs 100 crore investment for Ayush sector in Nagaland

Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram


Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases
Biotech | March 03, 2022

Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases

Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy


Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Biotech | March 03, 2022

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal


Trivitron Healthcare acquires U.S. based The Kennedy Company
Diagnostic Center | March 02, 2022

Trivitron Healthcare acquires U.S. based The Kennedy Company

This has further strengthened its manufacturing presence in the United States of America


Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review
Biotech | March 01, 2022

Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review

If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.


IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines
Biotech | March 01, 2022

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry


China’s NMPA accepts supplemental NDA for Carteyva
Drug Approval | February 28, 2022

China’s NMPA accepts supplemental NDA for Carteyva

The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China